Such a privilege to have amazing friends working on the same thing together all day everyday. Taking care of and finding therapeutic options for patients with #PancreaticCancer ! MSKCC Center for Pancreatic Cancer Research #fulfilling #life Fergus Keane Joshua Schoenfeld Eileen M O’Reilly

Pancreas Cancer 2024: Translating Genomic Findings into Clinical Actionability— Eileen M O’Reilly will address this topic in a keynote lecture at the AACR Special Conference on Advances in Pancreatic Cancer Research (September 15-18, Boston). bit.ly/3Wg3L7I #AACRpan24

Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/

🚨Such a delight to host a JAMA Oncology PODCAST with the amazing Eileen M O’Reilly Memorial Sloan Kettering Cancer Center - we talk about how an #AI based classifier reclassified approximately 20% of cases with pancreatic cancer. 👉🏼#immunotherapy for patients with Lynch syndrome or somatic MSI-H PanCAN

Best ⚡️talk for last!! Incredible presentation + poster on how hepcidin-mediated iron sequestration limits CD8+ tumor infiltrating lymphocytes in PDAC Joshua Schoenfeld 🧬😊

#TumorBoardTuesday 30% of all cancers are KRAS mutated‼️ And in #PancreaticCancer KRAS has been the most elusive🎯 📢So tune in Tuesday, 10-15-24 at 8PM ET as Wungki Park, MD MS & Brinda Alagesan🗣️targeting KRASG12D in Pancreatic Cancer RT and bring others into the discussion‼️

Sincerest thanks to Rich and Susan for their vision and generosity 🙏🏼😊 Honored to lead these efforts alongside PascaLab, timofran! We are so excited to implement this new support to rapidly expand on our achievements in the lab and to bring these to patients #GoBlue 💪🏼〽️

Congratulations Fergus Keane Catherine O’Connor Fiyinfolu (Folu) Balogun Drew Moss Eileen M O’Reilly and all our other amazing collaborators!

Rising 💫Drew Moss shares our experience MSK Department of Medicine in 1L chemoimmunotherpy in pancreatic neuroendocrine carcinoma (PanNEC): significantly high ORR (100%, N=5/5) & survival (mOS 33.6m vs 16.1m). Maybe we should test this in 1L!? Rohit Thummalapalli Diane Reidy-Lagunes #SITC24

Excited to share our latest in Nature Medicine✨ We present a detailed clinico-genomic landscape of pancreatic adenocarcinomas With important implications for RAS 🎯 therapies Expertly co-led by Anna Varghese and Maria A Perry. w/Eileen M O’Reilly & colleagues Memorial Sloan Kettering Cancer Center

Congratulations The National Pancreas Foundation . What an honor and delight for Memorial Sloan Kettering Cancer Center MSK Department of Medicine Eileen M O’Reilly to chair and lead your efforts for better science and care of all #pancreaticcancer patients worldwide

New in NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by Andrea Cercek & Luis Diaz) •100 % cCR in 49 rectal pts •65 % cCR across 10 other cancers (n=54) •Safe + all non-CR/recurs salvaged. =Use IO in NA for MMR-d tumors! nejm.org/doi/full/10.10…

The pancreatic cancer community hit a major setback when FY25 funding for the Pancreatic Cancer Research Program (PCARP) — the only federal program dedicated solely to researching pancreatic cancer — was eliminated. But, there’s still reason to be hopeful. 💜 We recently